Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
4(100.0%)
4Total
Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05597436Unknown

Intermediate-Sized Expanded Access Study

Role: lead

NCT05136885Phase 2Completed

HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose

Role: collaborator

NCT05490563Phase 2Terminated

STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia

Role: lead

NCT04669665Phase 2Completed

A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide

Role: lead

NCT05332678Phase 2Withdrawn

SLS-005 (Trehalose Injection) in the Treatment of Alzheimer's Disease

Role: lead

All 5 trials loaded